The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: essential differences and perspectives.
| Title: | The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: essential differences and perspectives. |
|---|---|
| Authors: | Goldstuck ND; Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Francie van Zyl Dr, Tygerberg Hospital, Bellville, South Africa. |
| Source: | The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception [Eur J Contracept Reprod Health Care] 2023 Jun; Vol. 28 (3), pp. 177-183. Date of Electronic Publication: 2023 Apr 12. |
| Publication Type: | Review; Journal Article |
| Language: | English |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 9712127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-0782 (Electronic) Linking ISSN: 13625187 NLM ISO Abbreviation: Eur J Contracept Reprod Health Care Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Informa Healthcare; Original Publication: Carnforth, Lancs, UK ; Pearl River, N.Y. : Parthenon Pub. Group, c1996- |
| MeSH Terms: | Contraceptive Agents, Female*/pharmacology ; Intrauterine Devices, Medicated*; Female ; Humans ; Aged ; Levonorgestrel ; Progesterone ; Estrogens |
| Abstract: | Background: It is 100 years since the discovery of oestrogen and nearly that since the discovery of progesterone. It is over 50 years since the concept of using intrauterine progesterone. Ten years after its synthesis, the research using levonorgestrel as an intrauterine agent was introduced.; Areas Covered: The pharmacodynamics and pharmacokinetics of LNG-IUSs and the LNG-IUS 52 mg in particular explain why intrauterine LNG is so highly effective for contraception. When intrauterine LNG is used therapeutically it should ideally be based on clinical monitoring of the pathology being treated rather than a fixed time period While the LNG-IUS 52 mg is probably required for most medical conditions, consideration should be given for using the LNG-IUS 13.5 mg for hyperplasia and endometrial protection during oestrogen therapy and for older women who appear more prone to a low rate of LNG induced breast cancer, although there is not yet an official indication for this.; Conclusion: The desire for fertility control, therapy for various genital pathological conditions and reduction of repeated endometrial decidualization and inflammatory breakdown and its consequences, and menopausal problems can be aided by intrauterine LNG. This review explains how a contraceptive also became a WHO listed essential medicine. |
| Contributed Indexing: | Keywords: Intrauterine; PALM-COEIN; contraception; levonorgestrel; therapy; Local Abstract: [plain-language-summary] There are significant differences at many levels in the use of intrauterine levonorgestrel for contraception when compared to using it as a therapeutic. |
| Substance Nomenclature: | 5W7SIA7YZW (Levonorgestrel); 4G7DS2Q64Y (Progesterone); 0 (Contraceptive Agents, Female); 0 (Estrogens) |
| Entry Date(s): | Date Created: 20230412 Date Completed: 20230612 Latest Revision: 20230612 |
| Update Code: | 20260130 |
| DOI: | 10.1080/13625187.2023.2197091 |
| PMID: | 37042204 |
| Database: | MEDLINE |
Review; Journal Article